Showing results (651-660 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|August 13, 2019
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialCristina Saura, Dominik Hlauschek, Mafalda Oliveira, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Lancet. Oncology|August 17, 2019
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
The Lancet. Oncology|August 19, 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysisScott J Antonia, Hossein Borghaei, Suresh S Ramalingam, et al.
The Lancet. Oncology|November 17, 2018
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyJoe-Elie Salem, Ali Manouchehri, Melissa Moey, et al.
The Lancet. Oncology|November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trialSuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
The Lancet. Oncology|October 9, 2019
Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic studyHuiyan Luo, Guoliang Xu, Chaofeng Li, et al.
The Lancet. Oncology|October 4, 2019
US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017Mallorie H Fiero, Jessica K Roydhouse, Jonathon Vallejo, et al.
Pageof 336